Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock - CYCCP STOCK NEWS

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) is set to announce its fourth quarter and full year 2022 financial results on March 6, 2023, at 4:30 PM ET. Following the announcement, a conference call will be hosted to discuss the results and company updates. Investors can access the call via toll-free numbers or webcasts. Cyclacel focuses on developing innovative cancer therapies, including the CDK2/9 inhibitor fadraciclib and the PLK1 inhibitor plogosertib. The company’s strategy aims to establish a diversified pipeline addressing oncology and hematology indications.

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) will present an overview of its business and clinical programs at the BIO CEO & Investor Conference on February 6-9, 2023. CEO Spiro Rombotis is scheduled to speak on February 6 at 9:30 AM ET in the Music Box room at the New York Marriott Marquis Times Square. The Company, focused on developing innovative cancer treatments, is available for meetings with attendees through the BIO One-on-One Partnering system. Cyclacel is advancing multiple drug candidates, including fadraciclib and plogosertib, targeting oncology and hematology indications. For more information, visit cyclacel.com.

Cyclacel Pharmaceuticals (CYCC, CYCCP) has made significant strides in 2022, focusing on its two leading drug candidates, fadraciclib and plogosertib, which are in Phase 1/2 clinical studies. The company anticipates starting Phase 2 trials for fadraciclib in 1Q 2023, following promising early results including 2/3 partial responses in T-cell lymphoma. With sufficient cash reserves projected to last through 2023, Cyclacel expects key data readouts this year, providing further insight into both drugs' efficacy and safety.

Cyclacel Pharmaceuticals plans to present at the Biotech Showcase and host meetings at a Corporate Access Event from January 9-11, 2023, in San Francisco. Spiro Rombotis, CEO, and Paul McBarron, EVP, will discuss the company's clinical advancements and goals. The Biotech Showcase presentation is on January 10 at 9:30 am PT at Hilton San Francisco Union Square. Cyclacel focuses on cancer therapies, particularly fadraciclib and CYC140, addressing solid tumors and hematological malignancies. For more details, visit www.cyclacel.com.

Cyclacel Pharmaceuticals reported on November 9, 2022, progress in its Phase 1/2 trials for oral fadraciclib and CYC140, with encouraging data showing tolerability and anticancer activity. In 18 evaluable patients, fadraciclib led to two partial responses in lymphoma and stable diseases in 11 cases of advanced solid tumors. The company expects to finalize the recommended Phase 2 dose by Q1 2023 and highlighted a cash runway extending to the end of 2023. Financially, cash equivalents were $23.7 million, with a net loss of $5.1 million for Q3 2022.

Cyclacel Pharmaceuticals announced it will report its third quarter 2022 financial results on November 9, 2022. A conference call and live webcast are scheduled for 4:30 PM Eastern Time on the same day. Cyclacel is focused on developing cancer medications based on cell cycle and transcriptional regulation biology, with drug candidates such as fadraciclib and CYC140 undergoing clinical evaluation. The company maintains a commitment to advancing its pipeline for oncology and hematology.

Cyclacel Pharmaceuticals reported promising data from its ongoing Phase 1/2 study of fadraciclib, a CDK2/9 inhibitor, for treating advanced solid tumors and lymphomas. Out of 18 evaluated patients, 2 out of 3 with T-cell lymphoma achieved partial responses, and 11 of 15 with solid tumors maintained stable disease. Notably, no dose-limiting toxicities were observed at dose levels up to 100mg BID. The study is advancing to the sixth dose level of 150mg BID. The company plans to present more data at the upcoming Research & Development Day on October 31, 2022.

Cyclacel Pharmaceuticals announced a research and development day on October 31, 2022, at 10 am ET, focusing on its CDK2/9 inhibitor oral fadraciclib and oral PLK1 inhibitor CYC140. The event will feature presentations from key opinion leaders on unmet medical needs in treating T-cell lymphomas and hepatobiliary cancers. Senior management will provide updates on patient data from the Phase 1/2 study for both drug candidates. A live Q&A will follow the presentations, offering insight into Cyclacel's oncology pipeline.

Cyclacel Pharmaceuticals will present preliminary dose escalation data for fadraciclib, a CDK2/9 inhibitor, at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics from October 26-28, 2022, in Barcelona, Spain. This Phase 1/2 clinical trial focuses on patients with advanced solid tumors and lymphoma. Fadraciclib aims to induce apoptotic cancer cell death and has shown efficacy in prior trials, providing positive outcomes for patients with certain cancer profiles. The presentation details include the study's title, abstract number, and schedule.